Evidence map›Paper›PMID 35085787›Full record

ArticleMolecular & cellular proteomics : MCP2022

Tuning DO:DM Ratios Modulates MHC Class II Immunopeptidomes.

Niclas Olsson, Wei Jiang, Lital N Adler, Elizabeth D Mellins, Joshua E Elias

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Niclas OlssonDepartment of Chemical and Systems Biology, Stanford School of Medicine, Stanford University, Stanford, California, USA.
Wei JiangDepartment of Pediatrics - Human Gene Therapy, Stanford University School of Medicine, Stanford University, Stanford, California, USA; Stanford Immunology, Stanford University School of Medicine, Stanford, California, USA.
Lital N AdlerDepartment of Pediatrics - Human Gene Therapy, Stanford University School of Medicine, Stanford University, Stanford, California, USA.
Elizabeth D MellinsDepartment of Pediatrics - Human Gene Therapy, Stanford University School of Medicine, Stanford University, Stanford, California, USA; Stanford Immunology, Stanford University School of Medicine, Stanford, California, USA. Electronic address: mellins@stanford.edu.
Joshua E EliasChan Zuckerberg Biohub, Stanford, California, USA. Electronic address: josh.elias@czbiohub.org.

Funding

Immunoglobulin as a novel ligand for HLA-DMR21AI095813 · NIAID · STANFORD UNIVERSITY · PI MELLINS, ELIZABETH D · 2011 to 2012
$435k
NIAID NIH HHS R21 AI095813
6 · The paper itself

Abstract

Major histocompatibility complex class II (MHC-II) antigen presentation underlies a wide range of immune responses in health and disease. However, how MHC-II antigen presentation is regulated by the peptide-loading catalyst HLA-DM (DM), its associated modulator, HLA-DO (DO), is incompletely understood. This is due largely to technical limitations: model antigen-presenting cell (APC) systems that express these MHC-II peptidome regulators at physiologically variable levels have not been described. Likewise, computational prediction tools that account for DO and DM activities are not presently available. To address these gaps, we created a panel of single MHC-II allele, HLA-DR4-expressing APC lines that cover a wide range of DO:DM ratio states. Using a combined immunopeptidomic and proteomic discovery strategy, we measured the effects DO:DM ratios have on peptide presentation by surveying over 10,000 unique DR4-presented peptides. The resulting data provide insight into peptide characteristics that influence their presentation with increasing DO:DM ratios. These include DM sensitivity, peptide abundance, binding affinity and motif, peptide length, and choice of binding register along the source protein. These findings have implications for designing improved HLA-II prediction algorithms and research strategies for dissecting the variety of functions that different APCs serve in the body.

Indexed as

Antigen PresentationHistocompatibility Antigens Class IIHLA-D AntigensProteomicsAntigen-Presenting CellsCell LineHLA-DR AntigensHumansPeptidesHistocompatibility Antigens Class IIHLA-D AntigensHLA-DR AntigensPeptidesantigen presentationDMDOHLAimmunopeptidomemass spectrometryMHCproteome

Identifiers

PMID35085787
PMCPMC10329146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.